98%
921
2 minutes
20
Background: One major factor contributing to infertility in women of childbearing age is premature ovarian insufficiency (POI). Exosomes produced from human umbilical cord mesenchymal stem cells (hUMSC-Exos) have drawn a lot of attention lately as a potential treatment for ovarian dysfunction brought on by POI. However, its therapeutic mechanism is still unclear and needs further exploration.
Methods: POI model was established by intraperitoneal injection of cyclophosphamide (CTX) in female Wistar rats. These POI rats were treated with hUMSC-Exos for one week. In addition to in vivo experiments, in vitro POI models were also established. In vitro experiments, theca interstitial cells (TICs) treated with CTX were exposed to normal as well as let-7a-5p inhibitory hUMSC-Exos. The ovary structure, morphology, endocrine function, and reproductive ability of POI rats were observed by H&E staining and ELISA. Western blot, immunofluorescence staining (IF), and quantitative real-time polymerase chain reaction (qRT-PCR) were used to evaluate the autophagy-related indexes in ovary and TICs of POI rats in each group.
Results: CTX induced abnormalities of ovarian morphology, structure, endocrine, and reproductive function in rats, and accompanied by autophagy of TICs. Notably, hUMSC-Exos diminishes ovarian structural and functional damage in POI rats and TICs autophagy via targeting the AMPK/mTOR pathway. Furthermore, downregulating let-7a-5p in hUMSC-Exos weakened their ability to prevent TICs autophagy.
Conclusions: Overall, the findings suggested that hUMSC-Exos improves ovarian function in POI rats by inhibiting TICs autophagy via the let-7a-5p/AMPK/mTOR pathway. Our study provided further evidence that POI patients can benefit from hUMSC-Exos-mediated therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145602 | PMC |
http://dx.doi.org/10.1186/s13287-025-04396-1 | DOI Listing |
Phytomedicine
August 2025
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; The second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. Electronic address:
Background: Premature ovarian insufficiency (POI) is a significant health issue for women under 40, characterized by declining ovarian function, hormonal imbalance, and various long-term health consequences. Current hormone replacement therapy (HRT) has limitations and potential risks. Thus, there is a need for safer and more effective therapeutic alternatives.
View Article and Find Full Text PDFInt J Nanomedicine
August 2025
Xu Rongxiang Regenerative Medicine Research Center, Binzhou Medical University, Yantai, People's Republic of China.
Background: Premature ovarian insufficiency (POI) is a persistent condition in young women characterized by early follicular development disorders and reduced fertility. Research has found that exosomes derived from human umbilical mesenchymal stem cells (hUCMSC-Exo) have significant tissue repair effects. This study aims to investigate the therapeutic effect and potential molecular mechanism of hUCMSC-Exo on POI.
View Article and Find Full Text PDFReprod Biomed Online
April 2025
Hunan Province Innovative Training Base for Medical Postgraduates, Hengyang Medical School, University of South China and Yueyang Women and Children's Medical Centre Yueyang, Hunan, China. Electronic address:
Research Question: Can the use of pyrroloquinoline quinone (PQQ) to treat premature ovarian insufficiency (POI) induced by cyclophosphamide (CTX) in rats restore ovarian function?
Design: Thirty female Sprague-Dawley rats were divided at random into three groups: control group (n = 10), POI group (n = 10), and POI-PQQ group (n = 10). An ovarian aging model was induced by CTX and treated with PQQ. The body weight of the rats was monitored throughout the process, and serum samples were collected to determine hormone concentrations.
Reprod Sci
August 2025
Lösante Hospital Ankara. Obstetrics and Gynecology Department, Kızılcaşar, 23 Nisan Cd. No:20.Gölbaşı, 06830, Ankara, Turkey.
Premature Ovarian Insufficiency (POI) may develop in young female patients due to chemotherapy treatments, which causes infertility. In addition to stem cell treatment, which is an effective method for POI in recent years, melatonin, which has high antioxidant properties, is also known to be effective. This study aimed to investigate the efficacy of melatonin, human umbilical cord-derived mesenchymal stem cell (hucMSC), and melatonin + human umbilical cord-derived mesenchymal stem cell (hucMSC) treatments on POI in cyclophosphamide-induced POI models in rats.
View Article and Find Full Text PDFJ Ovarian Res
August 2025
School of Basic Medical Sciences, Zhejiang Chinese Medical University, No.548 Binwen Road, Binjiang District, Hangzhou, 310053, Zhejiang, China.
Background: Premature ovarian insufficiency (POI) is a refractory gynecological endocrine disorder. Ningxin-Tongyu-Zishen formula (NTZF), developed based on the 'simultaneous heart-kidney regulation' principle, exhibits therapeutic efficacy in treating POI, potentially through regulating proBDNF/mBDNF balance. This study aimed to elucidate the molecular mechanism by which NTZF treats POI via proBDNF/mBDNF modulation.
View Article and Find Full Text PDF